Drugs / Vicineum
Vicineum
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03258593 | Jun 2018 → Aug 2022 | urinary bladder neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vicineum | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03258593 ↗ |
| Known as | Oportuzumab Monatox | “A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (Oportuzumab Monatox, VB4-845) in Subjects With High Grade Non-Muscle-Invasive Bladder...” NCT03258593 ↗ |
| Known as | VB4-845 | “A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (Oportuzumab Monatox, VB4-845) in Subjects With High Grade Non-Muscle-Invasive Bladder...” NCT03258593 ↗ |
| Modality | Protein / enzyme biologic | “Vicineum(TM) is a recombinant fusion protein” NCT03258593 ↗ |